Made available by Hasselt University Library in https://documentserver.uhasselt.be

Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy

Supplementary material

MARTENS, Pieter; VERBRUGGE, Frederik; NIJST, Petra; DUPONT, Matthias; Tang, W. H. Wilson & MULLENS, Wilfried (2017) Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy. In: AMERICAN JOURNAL OF CARDIOLOGY, 119(1), p. 65-70.

DOI: 10.1016/j.amjcard.2016.09.017

Handle: http://hdl.handle.net/1942/23282

Table 1: Baseline characteristics of the study population

Variable	Total population _ (n=541)	Iron deficiency		P value
		yes (n=301)	No (n=240)	
Demographics				
Age (years)	72.3 ± 10.4	71.9 ± 10.6	73.0 ± 9.8	0.212
Male	356 (65.8%)	184 (61.1%)	172 (71.7%)	0.01
BMI (Kg/m²)	26.9 ± 4.9	27.0 ± 4.7	26.7 ± 4.7	0.519
Cause of heart failure				0.152
Ischemic	244 (45.1%)	144 (47.8%)	100 (41.7%)	
Non-ischemic	297 (54.9%)	157 (52.2%)	140 (58.3%)	
Comorbidities				
Atrial fibrillation	205 (37.9%)	121 (40.2%)	84 (35%)	0.216
Obstructive lung disease	98 (18.1%)	58 (19.3%)	40 (16.7%)	0.435
Hypertension	433 (80.0%)	247 (82.1%)	186 (77.5%)	0.187
Dyslipidemia	376 (69.5%)	213 (70.8%)	163 (67.9%)	0.475
Diabetes	152 (28.1%)	96 (31.9%)	56 (23.3%)	0.028
Chronic kidney disease [¥]	255 (47.1%)	151 (50.2%)	104 (43.3%)	0.114
Device type				0.006
CRT-Pacemaker	275 (50.8%)	169 (56.1%)	106 (44.2%)	5.000
CRT-Defibrillator	266 (49.2%)	132 (43.9%)	134 (55.8%)	
Anemia	176 (32.6%)	105 (34.9%)	71 (29.7%)	0.202
Laboratory analysis				
Sodium (mmol/l)	138 ± 8	138 ± 10	138 ± 9	0.822
Hemoglobine (g/dl)	13.3 ± 1.7	12.9 ± 1.6	13.6 ± 1.7	0.0001
GFR (ml/min/1,73m²)	62.2 ± 24	60.2 ± 25	62.4 ± 24	0.325
NYHA class				0.145
II	221 (40.9%)	118 (39.2%)	103 (43.1%)	
III	298 (55.2%)	168 (55.8%)	130 (54.4%)	
IV	21 (3.9%)	15 (5.0%)	6 (2.5%)	
QRS duration (ms)	153 ± 29.4	151 ± 30.6	154 ± 27.9	0.229
Left Bundle Branch Block	404 (75.0%)	216 (72.2%)	188 (78.3%)	0.105
Echocardiography				
LVEF (%)	30 ± 9	30 ± 10	29 ± 9	0.082
LVEDD (cm)	6.1 ± 0.9	6.0 ± 0.9	6.1 ± 0.9	0.377
LVESD (cm)	5.5 ± 1.2	5.4 ± 1.1	5.6 ± 1.1	0.250
Medication				
Angiotensin converting	457 (84.6%)	254 (84.7%)	203 (84.6%)	0.979
enzyme inhibitor or	- (/	- ()	(2)	
angiotensin receptor blocker				
Beta-blocker	457 (84.6%)	250 (83.3%)	207 (86.3%)	0.350
Aldosterone antagonist	342 (63.3%)	193 (64.3%)	149 (62.1%)	0.590
Loop diuretic	273 (50.6%)	168 (56.2%)	105 (43.8%)	0.004
Nitrates	45 (8.3%)	23 (7.7%)	22 (9.2%)	0.531
Hydralazine	47 (8.7%)	28 (9.4%)	19 (7.9%)	0.554
Antiplatelet agent	296 (54.8%)	161 (53.7%)	135 (56.3%)	0.549
, mapiacoloc agoni	187 (34.6%)	123 (41.0%)	64 (26.7%)	0.001